Clinical Trials | January 01, 2026
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Subscribe To Our Newsletter & Stay Updated
